Biofuels’ Montagues and Capulets call a day to the multi-year legal fracas.

In Delaware and Colorado, Gevo and Butamax have entered into worldwide patent cross-license and settlement agreements, ending a patent dispute related to technologies for the production of bio-based isobutanol. This settlement ends all of the lawsuits and creates a new relationship between the companies, aimed at leveraging each other’s strengths and accelerating development of competitive supply for bio-based isobutanol.

The cross-license agreement grants both parties patent licenses to all fields for isobutanol and is structured to develop robust and sustainable isobutanol markets. The license will be royalty bearing for Butamax in certain fields and royalty bearing for Gevo in other fields. There are also a number of fields that are royalty-free for both companies. Both parties can sell up to 30 million gallons per year royalty-free into any field.

More on Gevo and Butamax

Butamax: The Digest’s 2015 5-Minute Guide

Gevo: The Digest’s 2015 5-Minute Guide

8-Slide Guides

Biobutanol breakout: The Digest’s 2015 8-Slide Guide to Gevo

Biobutanol breakout: The Digest’s 2015 8-Slide Guide to Butamax

Butamax to lead on road transport, Gevo on aviation

Butamax will take the lead role in developing the market for isobutanol as an on-road gasoline blendstock. This will include progressing ongoing programs to gain required EPA approvals for mainstream use of 16% isobutanol as a gasoline blend component. Butamax has also conducted joint research with Underwriters Laboratories (UL), which has demonstrated that these blends can be used safely in fuel storage and dispensing equipment meeting current UL standards. It is expected that UL’s guidance will clear the way for state government agencies to consider and approve the dispensing of biobutanol-gasoline fuel blends in the U.S.

In parallel, Gevo will lead development of the jet fuel market. Gevo has been producing and selling alcohol-to-jet fuel (ATJ) derived from isobutanol since 2011. To date, Gevo’s ATJ has been produced at its demo biorefinery in Silsbee, TX, using isobutanol produced at its Luverne, MN, fermentation facility. The company has successfully flown tests flights with the U.S. Air Force, U.S. Army, and U.S. Navy and now expects to secure the MIL-SPEC certification (JP-8 and JP-5) enabling bids on future RFPs for renewable jet fuel by the Defense Logistics Agency. Gevo also intends to begin test flights with the commercial aviation industry, including Alaska Airlines, following receipt of ASTM International certification, expected before the end of 2015.

The cross-licensing

While Butamax and Gevo have cross-licensed all of their patents for making and using isobutanol, both parties will have their own biocatalyst and process technologies. Both Butamax and Gevo are free to license their respective technology packages to third parties. A third party licensee would be granted a sub-license, and would be subject to terms and conditions that are consistent with the cross-license between Butamax and Gevo.

“We are very pleased to have reached this amicable and fair settlement. Setting up the marketing relationships, as we have done, brings to bear the capabilities of each of the companies,” said Dr. Patrick Gruber, Gevo’s Chief Executive Officer. “We very much look forward to developing a very large, growing and profitable isobutanol market in conjunction with Butamax.”

“The aim of these agreements is to accelerate development of markets for bio-based isobutanol,” commented Butamax Chief Executive Officer Paul Beckwith. “This will create exciting opportunities for ethanol producers to expand their businesses by becoming isobutanol producers, at the same time enabling the most competitive isobutanol supply for customers.”

Both parties have agreed to keep all details relating to these agreements confidential, other than what is disclosed in this press release and the attachment, or is otherwise required to be disclosed by law.

Analyst reaction

Cowen & Company’s Jeffrey Osborne writes:

The ongoing litigation has been a source of investor concern as it has led to increased operating expenses, higher cash burn levels and also likely delayed any license agreements in the U.S. given the ongoing litigation. We see the new agreement, signed this weekend ahead of the trial that was slated to start today as a long-term positive for the company. We are not making any changes to our estimates at this time.

This patent cross-licensing agreement will aim to leverage each company’s respective strengths to drive forward the development of bio-based isobutanol with the aim of developing a robust market for isobutanol. Per licensing agreement, Butamax and Gevo will be licensed to all fields, however, certain fields will be royalty bearing only for one of the respective companies and some fields will be royalty free for both companies.

Factsheet: Butamax and Gevo Patent Cross-License and Settlement Agreements

Butamax and Gevo have agreed to global settlement and cross license agreements resolving the ongoing intellectual property dispute and all current district court litigations will be dismissed by the parties.

Under the agreements Butamax and Gevo have licensed all of their respective patents to each other, with rights to sub-license their respective technologies.

Both parties are free to sell up to 30 million gallons per year royalty-free into any field, after which, certain fields bear royalties per the table image:

The parties have agreed to leverage each other’s regulatory approval and market development activities in order to accelerate the pace of market growth and to reduce duplication. Specifically:

Butamax will focus on gaining required approvals to support direct blending of bio-based isobutanol into on-road automotive gasoline, and is expected to market isobutanol for this application on behalf of both Butamax and Gevo.

Gevo will focus on gaining required approvals to support use of renewable ATJ made from bio-based isobutanol, and is expected to market isobutanol for this application on behalf of both Gevo and Butamax.

The licensing technology packages offered by Butamax and Gevo will differ at least as follows:

The parties will not exchange or utilize each other’s proprietary microorganisms.

The parties’ proprietary microorganisms will utilize different enzymes in the biobutanol pathway.

The parties’ process engineering designs will include different product recovery systems